buoyantintelligence
  • 01Overview
  • 02Portfolio
  • 03Company Atlas
    • Buoyant book
    • All listed companies
  • 04Screener & valuation
  • 05House view
  • 06Markets
  • 07India top-down
  • 08Investors
  • 09Library & data
Release
August 2026 · rev 1
Opportunities PMS · Published
As at 31 Aug 2026 · IST₹ · ₹ cr · BSE 500 TRI
Present
Internal working platform. Published figures are extracted from the August 2026 source package and reviewed; reference prices and fundamentals are unlicensed working data, not for redistribution. Past performance is not indicative of future returns.
All listed companies/Eris Lifesciences Limited
03 /Listed universe · Healthcare · Pharmaceuticals

Eris Lifesciences Limited.

Value itCompareScreener.in ↗Tijori ↗NSE ↗BSE ↗
Snapshot

Healthcare · Pharmaceuticals

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and anti-natal care solutions. It offers its products through wholesale drug distributors, stockists, retail and e-commerce pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is headquartered in Ahmedabad, India.

Market cap
₹17,656 cr
P/E (TTM)
27.4
P/B (latest)
4.5
ROE (TTM)
15.9%
ROCE (TTM)
16.8%
Sales CAGR 3y
22.9%
PAT CAGR 3y
17.5%
Debt / equity
0.59x
Promoter
54.1%
Dividend yield
—
Size
Small
Codes
ERIS · 540596
Price

₹1,219.3 · 29 Sept 2026

1M
−7.3%
3M
−13.3%
6M
−9.1%
YTD
−18.8%
1Y
−22.7%
3Y
+48.1%
5Y
—
vs 52w high
−28.3%

52-week ₹1,219.3 – ₹1,701.3 · ADTV ₹10.9 cr · price-only.

Trend

Sales and net profit by fiscal year, ₹ crore

Not in the Buoyant book: no house thesis or target is carried. Exchange masters, Tijori and the reference price feed as stated on each tab. All listed companies · NSE EQ